ArticleACG case reports journal2026
Vanishing Act: Spontaneous Regression of Hepatocellular Carcinoma After Hepatitis C Virus Treatment and Emergent Transjugular Intrahepatic Portosystemic Shunt Placement.
Article in ACG case reports journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We describe the case of a 71-year-old man with hepatitis C virus/alcohol-associated cirrhosis and a liver mass consistent with hepatocellular carcinoma (HCC) who experienced tumor regression after the initiation of direct acting antivirals and undergoing an emergent transjugular intrahepatic portosystemic shunt placement for variceal bleeding. Repeat imaging showed nonviable HCC despite no locoregional therapy, and liver explant pathology revealed <5% residual tumor. This is a rare instance of HCC regression potentially linked to viral eradication and portal pressure reduction. Understanding how direct acting antiviral therapy and transjugular intrahepatic portosystemic shunt influence tumor biology may offer insights into HCC management in decompensated cirrhosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.